[
    [
        {
            "time": "2023-07-04",
            "original_text": "格隆汇港股聚焦(7.04)︱旭辉控股上半年销售额超884亿元 华泰证券股东国信集团拟继续增持",
            "features": {
                "keywords": [
                    "旭辉控股",
                    "销售额",
                    "华泰证券",
                    "国信集团",
                    "增持"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "房地产",
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "格隆汇港股聚焦(7.04)︱旭辉控股上半年销售额超884亿元 华泰证券股东国信集团拟继续增持",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-07-04",
            "original_text": "港股异动 | 复星医药涨3.73% 子公司实体瘤治疗新药启动III期临床研究",
            "features": {
                "keywords": [
                    "复星医药",
                    "实体瘤",
                    "新药",
                    "III期临床研究"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "港股异动 | 复星医药涨3.73% 子公司实体瘤治疗新药启动III期临床研究",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        },
        {
            "time": "2023-07-04",
            "original_text": "中生制药续升逾2%领涨蓝筹 暂三连升兼三连阳",
            "features": {
                "keywords": [
                    "中生制药",
                    "续升",
                    "蓝筹"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中生制药续升逾2%领涨蓝筹 暂三连升兼三连阳",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-07-04",
            "original_text": "医药生物行业: 注册申请高增长, 审评通过高效率, 国产创新药迎来黄金收获期",
            "features": {
                "keywords": [
                    "医药生物",
                    "注册申请",
                    "审评通过",
                    "国产创新药",
                    "黄金收获期"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药生物行业: 注册申请高增长, 审评通过高效率, 国产创新药迎来黄金收获期",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-07-04",
            "original_text": "创新药盘点系列报告(11): 进击的疫苗, 深度盘点, 重磅迭出",
            "features": {
                "keywords": [
                    "创新药",
                    "疫苗",
                    "深度盘点",
                    "重磅"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "创新药盘点系列报告(11): 进击的疫苗, 深度盘点, 重磅迭出",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]